|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Division of Metabolism and Nutrition, Kinderklinik and Kinderpoliklinik, Dr. von Hauner Children's Hospital, Munich, Germany
Klinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-University, Munich, Germany
Published, JLR Papers in Press, October 1, 2002. DOI 10.1194/jlr.M200067-JLR200
1 To whom correspondence should be addressed. e-mail: berthold.koletzko{at}kk-i.med.uni-muenchen.de
| ABSTRACT |
|---|
|
|
|---|
These results suggest that only a part of the placental NEFA participated in fatty acid transfer, and that the placenta showed a preferential accretion of DHA relative to the other fatty acids.
Abbreviations: AA, arachidonic acid, C20:4n-6; APE, atom percent excess; DHA, docosahexaenoic acid, C22:6n-3; LA, linoleic acid, C18:2n-6; LC-PUFA, long-chain polyunsaturated fatty acids; NEFA, nonesterified fatty acids; PA, palmitic acid C16:0; PL, phospholipids; OA, oleic acid, C18:1n-9; TG, triglycerides
Supplementary key words fatty acids long chain polyunsaturated fatty acids placenta pregnancy stable isotopes
| INTRODUCTION |
|---|
|
|
|---|
Fatty acids are released from maternal triglycerides (TG) by lipoprotein lipase on the maternal surface of the placenta (68) and the liberated fatty acids, as well as nonesterified fatty acids (NEFA) from the circulation, can be utilized by the placenta. The placental transfer of fatty acids is considered a complex process that involves their binding to membrane proteins and cytoplasmatic transport proteins (8). Fatty acids may be esterified in the placenta and cross the tissue in either direction (8). Recently, in vitro studies have identified a placental plasma membrane fatty acid binding protein (p-FABPpm), which showed a higher affinity and binding capacity for DHA and AA compared with linoleic acid (LA, C18:2n-6) and oleic acid (OA, C18:1n-9) (9). Thus, p-FABPpm facilitates the observed preferential transfer of LC-PUFA. Kuhn and Crawford (10) reported that LA and AA were passed to the developing fetus in different lipid fractions during placental perfusion experiments, suggesting that a compartmentalization of fatty acids by the placenta might contribute to the selective transfer of some fatty acids.
In placental perfusion studies, nonesterified LA and palmitic acid (PA, C16:0) cross the placenta at similar rates (11, 12), and LA shows a relative preference for the transfer from the maternal to the fetal circulation compared with AA (10). From human placental perfusion studies, transfer selectivity of the placenta from the maternal to the fetal circulation has been reported to decrease from DHA to
-linolenic acid (ALA) to LA, to OA, and to AA (13). However, substrates may be metabolized within the placenta itself and the fatty acid release from albumin limits the rate of transfer of fatty acids across the tissue (14). Therefore, data derived from perfusion experiments may not reflect in vivo transfer of fatty acids.
Fatty acids labeled with stable isotopes are safe and can be used in pregnant women (15), allowing the study of human placental transport under in vivo conditions. Since the distribution of individual fatty acids in plasma and placenta might influence their selective materno-fetal transfer (10), we aimed at studying the placental transfer of [13C]PA, [13C]OA, [13C]LA, and [13C]DHA given orally to pregnant women before planned cesarean section.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Four hours before delivery, the subjects received one oral dose of uniformly (98%) 13C-labeled fatty acids (Martek, Bioscience, Columbia, MD) with 0.5 mg/kg body weight of [13C]PA, 0.5 mg/kg of [13C]OA, 0.5 mg/kg of [13C]LA, and 0.1 mg/kg of [13C]DHA. The tracers were supplied as free fatty acids on a sugar cube to the pregnant women, who were fasted for at least 12 h and did not eat during the study period.
Blood and placenta sampling
Blood samples were collected from the mothers before tracer intake (-4 h relative to cesarean section), and at -3 h, -2 h, -1 h, 0 h, and +1 h. Blood samples (3 ml) were taken by venipuncture and immediately transferred into EDTA-containing tubes. Venous cord blood was sampled immediately after clamping the cord. Blood cells and plasma were separated within 1 h by centrifugation at 1,000 g for 5 min. A plasma aliquot of at least 200 µl was frozen immediately at -80°C for later analysis.
The total placenta was weighed immediately after delivery. Samples of 1 x 1 x 1 cm of placenta cotyledons were cut with a sharp knife. Placenta samples were subjected to three washings with a 0.9% NaCl solution until blood was eliminated as far as possible, frozen in liquid nitrogen, and stored at -80°C until later analysis.
Analysis of plasma and placenta fatty acids
After addition of internal standard, total lipids from 0.1 ml of plasma were extracted into hexane-isopropanol (4:1, v/v) (16). Lipids from placenta tissue were extracted into chloroform-methanol (2:1, v/v) (17). For application on silica gel plates (MERCK, Darmstadt, Germany), the residue was taken up in chloroform-methanol (1:1, v/v). Phospholipids (PL), TG, cholesterol esters (CE), and NEFA were isolated by development of the plates in n-heptane-diisopropylether-glacial acetic acid (60:40:3, v/v/v) (18). Synthesis of fatty acid methyl esters was performed with 3M methanolic HCl (Supelco, Bellafonte, PA) at 85°C for 45 min. Derivatives were extracted into hexane and stored at -20°C until gas chromatographic analysis.
Gas chromatography was performed on a Hewlett-Packard 5890 series II gas chromatograph (Hewlett-Packard, Waldbronn, Germany) equipped with a BPX70 column (SGE, Weiterstadt, Germany) with 60 m length and 0.32 mm inner diameter (19). The 13C-enrichment of individual fatty acid methyl esters was measured by gas chromatography-combustion-isotope ratio mass spectrometry (Hewlett-Packard GC interfaced to Finnigan MAT delta S mass spectrometer, Bremen, Germany) (19).
Expression of the results
From the 13C/12C ratio of the samples measured by gas chromatography-combustion-isotope ratio mass spectrometry, the
13C relative to the international PDB (Pee Dee Belemnite) standard and the 13C atom percentage excess (APE) were calculated (20), representing the fatty acid enrichment evaluated. The concentrations of the labeled fatty acids (µmol/l or µmol/g) were calculated by multiplying the absolute concentrations of the fatty acids by their APE values.
As an estimation of the mean enrichment of tracer in the maternal plasma during all the experiment, we calculated the area under the curve from the µmol/l tracer of the individual fatty acids in the maternal plasma according the trapezoidal rule. The transfer ratio of the labeled fatty acids from the mother to the fetus was estimated by the percentage of tracer concentration (µmol 13C/l) in cord blood relative to the area under the tracer concentration curve in the maternal plasma (Table 4).
|
|
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Four hours after tracer ingestion, there is some enrichment of [13C]fatty acids in the maternal plasma TG and NEFA, while little has been esterified into PL and CE at this time (Fig. 1). However, since the placenta is reported to utilize almost exclusively fatty acids from maternal plasma TG and NEFA fractions for transfer to the fetus (8), we consider that this experimental design allows satisfactory evaluation of the transfer of the labeled fatty acids.
The 13C-enrichment of cord blood NEFA shows a trend to be higher than the [13C]enrichment in placental NEFA (Fig. 2) with statistically significant differences for NEFA OA and DHA, which lead us to conclude that there are different compartments of human placental NEFA. In agreement with this hypothesis, Hummel et al.(22) reported indications for the existence of two different pools of free fatty acids in rat placenta. They studied the placental transfer of [14C]PA administrated intravenously at intervals from 0.3 min to 300 min to pregnant rats. They described one compartment, accounting for only 5% of the total placental free fatty acids, which represented maternal free fatty acids passing across the placenta. The second compartment comprised 95% of the placental free fatty acids and appeared not to take part in materno-fetal fatty acid transport (22). If only a small part of placental NEFA is involved in the transfer, this could explain the relatively low enrichment of total NEFA in the placenta in the present study, since the enrichment measured by us is obtained from the mixture of both NEFA pools. Another possibility that could explain the lower enrichment in placental NEFA than in cord plasma NEFA would be a methodological error, since part of the placental PL might have been hydrolyzed by phospholipase A2 of the placenta (23) and have diluted the tracer in the NEFA fraction during the time span between delivery and sample freezing. However, the placental samples we studied were obtained and frozen in liquid nitrogen immediately after cesarean section, thus we assume that lipolysis should be minimal (24).
The lipid fraction in which the fatty acids are present in the placenta might influence their rate of transfer (Table 2). It is known that transient esterification is an intermediate step in the placental fatty acid transport of some of the NEFA. Szabo et al. (25) estimated that about 20% of isotope labeled palmitate was esterified in placental TG after 2 h of incubation of human placental tissue. Cultured human term trophoblast cells incubated with radiolabeled oleate for 24 h released to the medium high proportions of NEFA, while labeled PL and TG were retained in the cells (26). Thus, NEFA bound to cytosolic fatty acid binding proteins (8) are transferred into cord plasma faster than PL, CE, or TG. The synthesis of apolipoprotein B in rat placenta (27), and the identification of small amounts of lipoproteins very similar to LDL and VLDL in human term placentas (with most of the cellular PL and TG present in the preparation) (28), suggests a probable mechanism of exportation of the esterified fatty acids to the fetal side, which takes longer time than the transfer of NEFA.
Kuhn and Crawford (10) reported that perfused human placenta transferred [14C]AA mostly into fetal phosphoglycerides, which do not recross the placental barrier and thus may be retained in the fetal circulation, while [14C]LA was found mostly in NEFA, which may cross the placenta in either direction. A different compartmentalization of individual fatty acids by the placenta might be a powerful mechanism for selective transfer of fatty acids. In the present study, [13C]DHA was esterified in similar proportions into PL, TG, and NEFA of cord lipids (Table 3), while the other tracers were mainly incorporated into NEFA and TG, although the differences were not statistically significant. The relative esterification of [13C]DHA in cord PL in this study (37%) was lower than that reported for [14C]AA by Kuhn and Crawford (59.4%) (10). Differences in the distribution between DHA and AA were also described in BeWo cells where almost 37% of [14C]DHA was esterified into PL relative to the 60% for [14C]AA (29). The role of AA as precursor of eicosanoids might influence its selective accumulation in placental membrane PL and might explain differences to the placental transfer of DHA.
The concept of a preferential and selective transfer of LC-PUFA emerged from observations that maternal plasma lipids at birth contained higher percentage levels of the precursors ALA and LA than cord blood lipids of their infants, but percentage values for LC-PUFA were clearly and significantly higher in infants than in their mothers (3, 4). In contrast, some studies performed in human perfused placentas showed a higher rate of placental transfer for LA that for AA (10, 13). Haggarty et al. (30) recently reported that the fatty acid composition of the perfusate markedly modifies placental fatty acid transfer. While the selectivity for individual PUFA was DHA>ALA>LA>AA when the placenta was perfused with fatty acids in the same ratios as found in circulating TG of pregnant women in the last trimester of pregnancy, the preference changed to DHA> AA>ALA>LA when the maternal perfusate contained fatty acids in the same ratios as found in circulating NEFA.
In the present in vivo study, the tracer free fatty acids were administrated orally 4 h before delivery, and no preferential transfer of individual fatty acids across the placenta was detected (Table 4). However, we demonstrate a preferential sequestration of DHA into the human placenta relative to essential fatty acids and NEFA (Fig. 3). This result is in agreement with the preferential binding of maternal DHA by the FABPpm of the placenta described by other authors (8, 9). The DHA uptake in placental tissue might play an important role for the DHA transfer. Haggarty et al. (13) did not detect any preferential accumulation of [14C]DHA in the perfused human placenta, but they found a preferential materno-fetal transfer of DHA. It appears possible that DHA transfer is a slow stepwise process, with initial placental uptake of DHA and later release into the fetal circulation. Our experiment may have detected mostly the first part of this process occurring until 4 h after tracer administration. Since we could not detected enrichment of tracer in PL and CE in the maternal side, it is unlikely that the time was sufficient to investigate the transfer of labeled fatty acids involving these components. Further studies with longer time intervals between tracer administration and delivery might contribute to describing the transfer process. It is likely that the results obtained 8 h, 12 h, or 24 h after administration of the labeled isotopes would be considerably different, but longer time frame studies also imply dilution of tracer by dietary intake and the fatty acids transferred quickly to the fetus as NEFA might already have been incorporated into fetal tissues.
In conclusion, the results of the present study demonstrate that stable isotope labeled fatty acids administrated 4 h before delivery to pregnant women appear in maternal TG and NEFA, but hardly in PL. The 13C-enrichment of cord blood NEFA tended to be higher than the 13C-enrichment in placental NEFA, which we interpret to reflect the existence of different pools of placental NEFA. Placental tissue shows a preferential incorporation of DHA relative to LA, OA, and PA at the studied time point, which may reflect a metabolic mechanism for a preferential materno-fetal DHA transfer.
| ACKNOWLEDGMENTS |
|---|
Manuscript received February 7, 2002 and in revised form July 17, 2002.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. T. Schaiff, F. F. Knapp Jr., Y. Barak, T. Biron-Shental, D. M. Nelson, and Y. Sadovsky Ligand-Activated Peroxisome Proliferator Activated Receptor {gamma} Alters Placental Morphology and Placental Fatty Acid Uptake in Mice Endocrinology, August 1, 2007; 148(8): 3625 - 3634. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Krauss-Etschmann, R. Shadid, C. Campoy, E. Hoster, H. Demmelmair, M. Jimenez, A. Gil, M. Rivero, B. Veszpremi, T. Decsi, et al. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial Am. J. Clinical Nutrition, May 1, 2007; 85(5): 1392 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Szajewska, A. Horvath, and B. Koletzko Effect of n-3 long-chain polyunsaturated fatty acid supplementation of women with low-risk pregnancies on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1337 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lehner, H. Demmelmair, W. Roschinger, T. Decsi, M. Szasz, K. Adamovich, R. Arnecke, and B. Koletzko Metabolic effects of intravenous LCT or MCT/LCT lipid emulsions in preterm infants J. Lipid Res., February 1, 2006; 47(2): 404 - 411. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |